drugset / Trial / NCT01078714

Efficiency of Bumetanide in Autistic Children

NCT01078714

Phase 3 Completed 60 enrolled University Hospital, Brest
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism

Timeline

Start
2010-03
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bumetanide Small molecule 0.5 mg Oral